Equities

PeptiDream Inc

PeptiDream Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,615.00
  • Today's Change-21.00 / -1.28%
  • Shares traded447.50k
  • 1 Year change-55.63%
  • Beta1.1096
Data delayed at least 20 minutes, as of Sep 30 2022 03:30 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

  • Revenue in JPY (TTM)11.51bn
  • Net income in JPY1.78bn
  • Incorporated2006
  • Employees141.00
  • Location
    PeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
  • Phone+81 442701300
  • Websitehttps://www.peptidream.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zeria Pharmaceutical Co Ltd62.29bn5.15bn105.97bn1.74k17.301.559.971.70115.29115.291,389.741,286.970.49421.463.9435,860,130.004.103.106.944.9871.6071.288.305.920.70697.180.484845.8712.84-1.7026.032.25-17.521.81
Shin Nippon Biomedical Laboratories Ltd18.75bn7.25bn106.04bn994.0014.635.0312.505.65174.04174.04450.47506.150.4541.867.2018,866,960.0017.615.0625.677.6554.2845.4838.7914.970.9192--0.379724.1317.460.577894.65--9.71--
TOWA PHARMACEUTICAL CO., LTD168.06bn12.00bn106.84bn4.08k8.700.76024.390.6358238.37238.373,339.212,728.220.58221.453.4041,211,380.004.165.915.817.8540.8244.127.1410.220.7652--0.508016.486.9214.2814.0123.34-8.5012.47
KYORIN Holdings, Inc.105.46bn5.58bn111.38bn2.22k17.710.790211.931.0697.3397.331,840.392,181.680.63041.382.7947,460,850.003.333.334.044.0346.9151.065.295.462.25--0.144370.592.56-1.77-35.86-11.650.338-2.16
Kissei Pharmaceutical Co Ltd65.03bn10.91bn129.17bn1.83k10.540.56938.681.99236.63236.631,410.194,379.430.26191.752.9635,574,940.004.443.164.763.4248.4755.9816.9410.455.03--0.00834.12-5.31-1.83144.4810.83-5.394.01
Mochida Pharmaceutical Co., Ltd.110.51bn11.07bn132.13bn1.54k11.290.95049.631.20291.39291.392,913.733,461.720.68092.273.6071,573,180.006.825.228.256.4054.1651.5710.027.763.58--0.0040.566.982.5123.084.3921.993.04
Sosei Group Corporation17.05bn-224.00m144.35bn198.00--2.56134.408.47-2.73-2.73208.57688.040.1975--10.9686,090,910.00-0.2596---0.2705--94.03---1.31----1.140.3447--100.32---31.24------
KAKEN PHARMACEUTICAL CO., LTD.75.78bn9.09bn172.50bn1.16k15.641.0314.882.28240.14240.142,001.903,646.730.46142.113.6965,101,380.005.5410.156.3412.0654.5556.0912.0018.284.89--0.027237.001.41-5.61-28.77-15.396.710.00
Sawai Group Holdings Co Ltd191.56bn-30.91bn175.17bn2.97k--0.8933--0.9144-706.09-706.094,370.554,478.040.50561.502.8564,542,120.00-11.771.25-16.271.7033.0638.97-23.272.461.39-140.920.266976.823.527.92-329.08--4.380.00
TAKARA BIO INC.66.53bn17.73bn202.90bn1.67k11.442.079.213.05147.25147.25552.50815.460.63021.175.2139,933,370.0016.869.9419.4411.1669.4465.3726.7618.173.6239.330.0021.0346.9018.17107.9171.1452.5752.51
Peptidream Inc11.51bn1.78bn208.80bn141.00117.188.4373.1618.1413.7113.7188.66190.550.30232.974.15--4.67--5.24--61.41--15.46--2.08--0.4666---19.79---18.93------
Tsumura & Co132.19bn20.08bn230.66bn3.92k11.450.92227.611.74262.45262.451,727.843,258.350.38340.71242.4333,713,850.006.045.197.486.2851.4055.7815.7512.783.03--0.155931.4511.282.4222.858.574.990.00
JCR Pharmaceuticals Co Ltd50.88bn14.34bn264.82bn816.0017.694.9816.265.21115.46115.46409.53410.130.60290.76414.9862,346,810.0017.0111.4728.7116.2777.8573.5828.2120.621.17--0.26222.4669.7923.08110.4950.7548.8629.46
Hisamitsu Pharmaceutical Co Inc118.83bn8.93bn277.21bn2.78k29.411.0420.452.33110.68110.681,471.373,133.610.39112.773.6942,681,390.003.025.153.435.8357.4161.167.7211.524.20--0.00544.974.96-3.814.41-13.895.560.6061
Data as of Sep 30 2022. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

28.38%Per cent of shares held by top holders
HolderShares% Held
Taiyo Pacific Partners LPas of 29 Aug 20229.36m7.20%
JOHCM (Singapore) Pte Ltd.as of 24 Aug 20215.75m4.42%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Mar 20224.72m3.63%
Invesco Advisers, Inc.as of 31 Jul 20223.05m2.35%
Baillie Gifford & Co.as of 30 Jun 20223.01m2.32%
Nomura Asset Management Co., Ltd.as of 31 Aug 20222.98m2.30%
The Vanguard Group, Inc.as of 09 Sep 20222.23m1.72%
Nikko Asset Management Co., Ltd.as of 31 Mar 20222.01m1.55%
Alma Capital Investment Management SA (UK)as of 30 Jun 20221.95m1.50%
BlackRock Fund Advisorsas of 30 Nov 20211.82m1.40%
More ▼
Data from 30 Sep 2019 - 29 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.